Executive order to raise drug price transparency is signed by DeSantis
"I think it's going to be very, very meaningful."
Gov.
Gov.
The point of the executive order is to ultimately lower the price of prescription drugs. DeSantis said. He said that with the rise in food and gas costs, addressing the price of pharmaceuticals is one area he could "make a difference."
"This executive order is really probably the first time
The order would help make pharmacy benefit managers, third-party administrators of prescription drug programs, accountable when managing prescription drug benefits for insurance companies.
"
The order directs all executive agencies to include the following in all future contracts with PBMs:
Prohibit spread pricing
Prohibit reimbursement claw backs
Include data transparency and reporting requirements
Review all rebates, payments and relationships between pharmacies, insurers and manufacturers
Amend all current contracts they can with the same provisions
In a news release sent Friday, Jackson applauded DeSantis on the executive order.
"We are encouraged by this latest development – which follows the passage of House Bill 357 — and the governor's continued commitment on this critical issue facing so many Floridians and their families," Jackson said.
House Bill 357, which went into effect
"We're going to use the executive order as our baseline and we're going to look for more ways to ensure that we are saving taxpayers money and we are ensuring that independent and small pharmacies can serve not only the Medicaid population, but all members of this community without going out of business at the hands of PBMs."
The biggest hurdle though, according to DeSantis and Marstiller, is the
The executive order isn't the only thing the state has done to try and lower prescription drug prices, according to DeSantis. The state's Canadian Prescription Drug Importation Program has been under review by the FDA for nearly 600 days.
This program, if approved, would allow prescriptions drugs to be imported to
ACHA filed a Freedom of Information Act to find out why the program has been stalled.
DeSantis pointed out that while the FDA was quick to approve COVID-19 vaccines for children, and the import of baby formula, the agency has taken its time when it comes to
"It's interesting when you look at the FDA dragging their feet on what we're trying to do, which is buy cheaper drugs," DeSantis said.
"I think it's going to be very, very meaningful."
Gov.



Louisiana Extends Ida Mediation Program Through End of 2022
Musk abandons deal to buy Twitter; company says it will sue
Advisor News
- How smart investments prepare clients for inflation
- Amid slew of corporate tax ideas, Newsom chose one likely to hit people’s premiums
- The biggest risk to your clients’ financial plans isn’t market volatility
- Initiative looks at how caregiving impacts workplace benefits
- Will rising retirement needs spark an annuity boom?
More Advisor NewsAnnuity News
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
- Fortitude Re Completes $500 Million FABN Issuance
- Reframing retirement income for greater certainty
- Jackson Introduces Dow Jones Industrial Average Index Option, Flexible Premiums, Six-Year Rate Guarantee in Latest Registered Index-Linked Annuity Launch
- Senior Market Sales® Fortifies Annuity Reach With Acquisition of Retirement Planning Firm Stratton & Company
More Annuity NewsHealth/Employee Benefits News
- Final rules for Medicaid work requirements are out. Here's what you need to know.
- Hyde-Smith blasts health care delays
- WNY health insurers seek rate hikes of 9% to 24% for 2027
- Healthcare now costs more than mortgages
- Fairview won’t accept seniors with UnitedHealth Medicare Advantage plans next year
More Health/Employee Benefits NewsLife Insurance News
- AM Best Affirms Issue Credit Ratings of Weston2038 LLC’s Credit-Linked Notes
- Globe Life Inc. (NYSE: GL) Records 52-Week High Thursday Morning
- Greg Lindberg moves to halt $1.65B restitution order, claims he ‘overpaid’
- Fidelity Investments® to Expand Target Date Lineup With Launch of Guaranteed Income Solution
- KBRA Releases Research – Private Credit: Much Ado About Nothing – Perspectives on Columbia Business School Paper About Private Ratings
More Life Insurance News